PRESCRIBED ANTINEOPLASTIC AGENTS IN PAEDIATRIC PATIENTS

BLACKGROUND

Many medicines prescribed for children have not been formally studied. Therefore, most of them are not labeled to be used in paediatric patients. The Regulation (EC) No-1901/2006 on medicinal products for paediatric use sets up several requirements, rewards and incentives to promote medicinal products being researched, developed and authorized covering the therapeutic needs of children.

PURPOSE

To evaluate the prescription profile of antineoplastic agents in paediatric patients in two relevant hospitals in Paediatrics that belong to a Regional Health Service.

MATERIALS AND METHODS

Descriptive study of antineoplastic drug prescription in paediatric patients in Oncology and Hematology Departments during 2017.

RESULTS

A total of 220 children were included (average age: 7.77 years).

- 4CPS-105

CONCLUSIONS

Despite Regulation (EC) No-1901/2006, the results of our study show that around two thirds of the children received at least one unlicensed or off-label antineoplastic agent.

Proper clinical studies demonstrating and supporting the use of effective and safe drugs on PP are required.